Fire Fox,
You said.
If you try to do (4) before (2) and (3), which is what some posters on this Board seem to want, the post-split value of the pps may go to $100, but it won't go to $200 or $300.
Do you have any back up that shows other small biotech companies in similar situations?
In my opinion, if the company added a well qualified COB before new data is presented at ASCO, it would help the share price long term, not hinder it.
mojo